In March, the US Food and Drug Administration (FDA) granted Cereno Scientific’s preclinical candidate CS-1 (valproic acid) Orphan Drug Designation for pulmonary arterial hypertension.
GlobalData supposes that CS-1 could fill a gap in the market due to its innovative mechanism of action, particularly epigenetic modulation of cardiovascular disease by histone deacetylase inhibition.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
